2019-05/14
United BioPharma Receives China NMPA Approval for UB-421 Phase 3 ART-Substitution Trial in HIV-infected Patients
1
2019-04/18
Effect of Anti-CD4 Antibody UB-421 on HIV-1 Rebound after Treatment Interruption(N Engl J Med 2019; 380:1535-1545)
2
2019-04/18
United BioPharma Announces Publication of Breakthrough HIV Clinical Trial Data in the New England Journal of Medicine
3
2019-04/18
How an Experimental Injection Could Revolutionize HIV Treatment
4
2019-05/21
United Biopharma obtains approval from the U.S. FDA to conduct a clinical trial with UB-421 in Patients with Multi-Drug Resistance HIV-1 infection
5
2019-04/18
Novel antibody may suppress HIV for up to four months
6
2019-04/17
Monoclonal antibody demonstrates ‘unprecedented’ virologic suppression in HIV study
7
2019-04/17
Weekly Infusion May Be Effective, Easier HIV Therapy
8
2018-12/06
United BioPharma obtained Taiwan FDA approval for conducting phase I clinical trial of its UB21 product, a third generation monoclonal anti IgE antibody
9
2019-05/14
United BioPharma Receives China NMPA Approval for UB-421 Phase 3 ART-Substitution Trial in HIV-infected Patients
1
2019-04/18
Effect of Anti-CD4 Antibody UB-421 on HIV-1 Rebound after Treatment Interruption(N Engl J Med 2019; 380:1535-1545)
2
2019-04/18
United BioPharma Announces Publication of Breakthrough HIV Clinical Trial Data in the New England Journal of Medicine
3
2019-04/18
How an Experimental Injection Could Revolutionize HIV Treatment
4
2019-05/21
United Biopharma obtains approval from the U.S. FDA to conduct a clinical trial with UB-421 in Patients with Multi-Drug Resistance HIV-1 infection
5
2019-04/18
Novel antibody may suppress HIV for up to four months
6
2019-04/17
Monoclonal antibody demonstrates ‘unprecedented’ virologic suppression in HIV study
7
2019-04/17
Weekly Infusion May Be Effective, Easier HIV Therapy
8
2018-12/06
United BioPharma obtained Taiwan FDA approval for conducting phase I clinical trial of its UB21 product, a third generation monoclonal anti IgE antibody
9
